๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients

โœ Scribed by Maria J. Tasso; Alan V. Boddy; Lisa Price; Ruth A. Wyllie; Andrew D. J. Pearson; Jeffrey R. Idle

Publisher
Springer
Year
1992
Tongue
English
Weight
542 KB
Volume
30
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Cyclophosphamide pharmacokinetics and do
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency
โœ Haubitz, Marion; Bohnenstengel, Frank; Brunkhorst, Reinhard; Schwab, Matthias; H ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› Nature Publishing Group ๐ŸŒ English โš– 219 KB

## Background: Intravenous pulse administration of cyclophosphamide (cyc) has been successfully used for the treatment of various autoimmune diseases. these patients often present with impaired renal function or even end-stage renal failure. nevertheless, data concerning pharmacokinetics of cyc in

Pharmacokinetics of (R)- and (S)-cycloph
Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients
โœ Marion L. Williams; Irving W. Wainer; Camille P. Granvil; Barbel Gehrcke; Mark L ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 207 KB

The complete pharmacokinetics (PK) of (R)-and (S)-cyclophosphamide (CP) and their dechloroethylated (DCE) metabolites have not been reported to date. We collected plasma and urine samples from 12 cancer patients and determined concentrations of both enantiomers of CP and DCE-CP using a chiral GC-MS

Metabolism of cyclophosphamide
Metabolism of cyclophosphamide
โœ Prof. Dr. med. N. Brock; H.-J. Hohorst ๐Ÿ“‚ Article ๐Ÿ“… 1967 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 294 KB

The in vivo activation of cyclophosphamide (Endoxan) to cytostatic and alkylating metabolites has been studied. Endoxan is metabolized to the weak anion by microsomal dealkylation in the rat's liver; this product is the first alkylating metabolite. About 80% of the alkylating activity of the serum,